Raphael Pharmaceutical Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Balance Sheets (PCAOB ID No. 6816)
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
| As of September 30, | As of December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | (Audited) | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40 | $230 |
| Other current assets | 9 | 107 |
| Total current assets | 49 | 337 |
| Fixed assets, net | 2 | 2 |
| Total assets | $51 | $339 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Other account payables and accrued expenses | 537 | 34 |
| Payable to related party | 130 | 38 |
| Total current liabilities | 667 | 72 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.01 par value: | ||
| Authorized: 50,000,000 shares at September 30, 2024, and 21,020,560 shares at December 31, 2023; | ||
| Issued and outstanding: 18,701,418 and 18,502,918 at September 30, 2024 and December 31, 2023, respectively; | 187 | 185 |
| Additional paid-in capital | 7,631 | 7,392 |
| Accumulated deficit | (8,434) | (7,310) |
| Total stockholders’ equity (deficit) | (616) | 267 |
| Total liabilities and stockholders’ equity | $51 | $339 |
-F-2-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.